Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Sexual activity and vaginal dilation associated with fewer side effects after cervical cancer treatment

Written by | 4 Oct 2023

People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical cancer are at lower risk for long-term side effects, according to a new study… read more.

FDA grants priority review to application for Keytruda + concurrent chemoradiotherapy, as treatment for newly diagnosed high-risk locally advanced cervical cancer – Merck Inc

Written by | 25 Sep 2023

Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking… read more.

Tivdak improved overall survival in patients with recurrent or metastatic cervical cancer compared with chemotherapy alone – Seagen + Genmab

Written by | 7 Sep 2023

Seagen Inc. and Genmab A/S announced that the Phase III innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line… read more.

Mailing at-home HPV sampling kits nearly doubles cervical screening uptake among hard-to-reach populations, US clinical trial suggests

Written by | 15 May 2023

At-home high-risk human papillomavirus (hrHPV) sampling kits can help increase cervical cancer screening among under-screened women from low-income backgrounds, according to findings from a US-based clinical trial published… read more.

New smoking cessation intervention helps patients with cervical cancer precursor or cervical cancer quit smoking

Written by | 20 Mar 2023

Tobacco use is the leading preventable cause of death in the U.S., accounting for about 1 in 5 deaths each year. It is also a risk factor for… read more.

FDA approves Keytruda plus chemotherapy for cervical cancer – Merck

Written by | 22 Jan 2022

Merck Inc., announced that the FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic… read more.

Merck Inc announces phase III KEYNOTE-826 trial met dual primary endpoints of overall survival and progression-free survival in patients with persistent, recurrent or metastatic cervical cancer

Written by | 2 Jul 2021

Merck Inc., announced that the pivotal Phase III KEYNOTE-826 trial investigating Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with… read more.

Adjuvant chemotherapy does not improve mortality in locally advanced cervical cancer

Written by | 22 Jun 2021

Article written by Bruce Sylvester. In locally advanced cervical cancer, use of adjuvant chemotherapy after standard chemoradiation does not improve mortality outcomes. Researchers reported this finding on June… read more.

Human papilloma virus (HPV) and cervical cancer

Written by | 10 Mar 2021

Interview and article by Christine Clark Cervical cancer accounts for about 850 cancer deaths in the UK every year – more than two every day – and yet… read more.

HPV vaccination significantly lowers risk of cervical cancer

Written by | 21 Nov 2020

Article written by Bruce Sylvester. HPV (human papillomavirus) vaccination appears to significantly lower the risk of cervical cancer, researchers reported on Sept. 30, 2020 in the NEJM/New England… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.